Trellis Vitality Review: $150 Semaglutide, and a Gap

Trellis Vitality (trellisvitality.com) sells five clinician-guided injectable programs and publishes the best-formed GLP-1 price table of any provider we screened in August 2026. It also publishes a claim about its own transparency that is not true. Both of those belong in the same review.

The GLP-1 table, which is genuinely good

Semaglutide is $150 a month on a one-month plan, $140 a month on three months, and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three columns.¹ The table is labeled "per-month price; longer plans cost less per month", and all dosages are the same price.

That structure matters more than the numbers. The one-month column is explicitly the month-to-month rung, so nothing here requires you to reverse-engineer a prepay total into a monthly figure — the failure mode that puts a fake cheap price at the bottom of half the rankings in this market. At $150, Trellis is the second-cheapest verified month-to-month semaglutide in this batch, behind Pepti and ahead of Auren Rx at $199 and The Edit at $209.

The gap: everything that is not GLP-1

The other four programs publish one number each and no ladder at all. NAD+ is "treatment plans starting at $129/month". Glutathione is "starting at $93/month". Lipo-MIC with B12 is "starting at $130/month". Tesamorelin is "starting at $299/month". There is no rung table behind any of them — not on the program pages, not in the site's build output, not in the intake flow.

We are not publishing those as monthly prices, and neither should anyone else. Look at the shape of the GLP-1 table: its six-month rung sits about 12 percent below its one-month rung. If the same structure applies to NAD+, then $129 is the six-month prepay rate and the actual month-to-month rate is higher. That is a reasonable inference. It is not an observation, so it stays unverified and the honest way to quote Trellis on NAD+ is "from $129 a month, full ladder not published".

The claim that does not hold

Trellis's own blog states, twice, that the company publishes its complete pricing on the program page. It does not. One program page publishes a complete ladder; four publish a single starting-at figure. This is a small thing and an avoidable one, and it is exactly the kind of claim a reader should check rather than accept — the general habit argued for in how to tell if a GLP-1 provider is legit.

There is a second set of numbers on the site worth ignoring: a 4.7 out of 5 rating, "5,000+ current patients", "3.4 weeks average time saved" and "$4,000 average patient savings per year". None is sourced anywhere. We do not repeat unsourced marketing statistics, and we would not build a decision on them.

Who prescribes, and who dispenses

The clinical group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director. His NPI, 1841729449, resolves to an active Family Medicine record in the national registry.² The pharmacy is VialsRX, a state-licensed compounding pharmacy in Houston, Texas — named openly, which most of this cohort does not do.

The thing to know before you shortlist: The Edit uses the same medical group and the same medical director. The pharmacies differ, the prices differ, and they are separable products — but they are not two independent clinical opinions, and treating them as two alternatives on a shortlist would be a mistake.

What is not disclosed

Trellis does not publish a corporate legal entity. Its terms page is roughly three kilobytes of text and does not name an LLC or a corporation as the operator. It says it serves all 50 states and advertises no membership and no consult cost, with a free initial assessment — but the thin terms document does not corroborate the fee claims, so those rest on marketing copy alone.

The regulatory screen

The trading name, the medical group and the pharmacy all returned zero matches in the FDA's live warning-letter index when we queried it in August 2026.³ The same pass correctly returned a known 2026 letter for an unrelated telehealth seller used as a positive control, so the clean result reflects a working query rather than a broken one.

Where it lands

For compounded GLP-1, Trellis is one of the two or three cleanest specimens in this batch: a published table, a named pharmacy, a verifiable prescriber, and no prepay trick. For NAD+ or any of its other programs, it is a provider you cannot price without contacting it. Those are different verdicts about the same company, and we would rather say so than average them. More context in our evidence library and in how to choose a GLP-1 provider; for a strict price sort, see the cheapest tirzepatide ranking.